Inpharma Weekly

, Volume 1062, Issue 1, pp 7–8 | Cite as

New targets may lead to novel classes of anti-obesity drugs

  • Gill Higgins
Newsletter Article


Although a number of appetite suppressants are now in clinical trials, the search for new anti-obesity drug targets continues. Recent advances in basic science have unveiled 2 new receptors that may prove to have potential in this field. They are the neuropeptide Y (NPY)-5 receptor and the peroxisome proliferator activated receptor (PPAR)-γ. These possible new approaches to the treatment of obesity were discussed at the 3rd IBC USA conference on ‘Obesity - Advances in Understanding and Treatment’ [ San Diego, US; September 1996 ].


Obesity Feeding Behaviour Peroxisome Proliferator Activate Receptor Pancreatic Polypeptide Eicosan 

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations